Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
24 hedge funds and large institutions have $336M invested in Kaleido Biosciences, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$239M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.9M |
| 3 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$16.1M |
| 4 |
AG
Artal Group
Luxembourg
|
+$13M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$11.9M |
Top Sellers
KLDO Hedge Fund Activity: Q1 2019 in Review
24 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q1 2019, worth a combined $336M.
Buyers outnumbered sellers: 24 funds opened new KLDO positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Flagship Pioneering, opening a new position worth an estimated $239M.
- 24 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $336M of Kaleido Biosciences, Inc. Common Stock stock for Q1 2019.
- 24 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q1 2019 and 0 closed out, a net change of +24 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q1 2019 was Flagship Pioneering, an estimated $239M added.
Based on aggregated 13F filings for Q1 2019.